| HOME >> BIOLOGY >> TECHNOLOGY |
Technology expected to aid drug discovery by allowing for the rapid
synthesis of molecules using a single reaction
ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce that it has signed an exclusive licensing agreement with the University of Illinois at Urbana-Champaign allowing Sigma-Aldrich to offer research quantities of powerful new boronic acid surrogates for use in Suzuki-Miyaura coupling to researchers worldwide (http://sigma-aldrich.com/mida). Under the terms of the agreement, Sigma-Aldrich can also satisfy commercial-scale requests for these surrogates from its manufacturing customers.
Developed by Professor Martin Burke and co-workers, the technology has powerful implications for drug discovery, where the ability to quickly create large sets of related small molecules for use in screening is critical. The advancement relies on the use of a simple, low-cost, and environmentally-friendly ligand (N-methyliminodiacetic acid, "MIDA") that reversibly modulates boronic acids toward cross-coupling. The MIDA-ligated boronic acid building blocks can be used to construct target molecules using a single cross-coupling reaction in an iterative process, in a fashion resembling peptide synthesis. Complex bioactive molecules can also be efficiently constructed, as demonstrated in recent publications from the Burke research group in 2007 and 2008.
"Sigma-Aldrich has a nearly 40-year history of developing boron
reagents for use by the chemical community, and we are delighted to
maintain our leadership position in this area by garnering access to this
potent technology," said Nate Wallock, Chemistry technology transfer
manager at Sigma-Aldrich. "In collaboration with the Burke group, our R&D
groups have actively developed the syntheses of dozens of MIDA boronic acid
derivatives, many of which will be available globally in the comi
'/>"/>
| SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
2. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
3. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
4. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
5. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
6. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
7. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
8. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
9. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
10. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
11. Sigma-Aldrich Announces Collaboration to Develop Monoclonal Antibodies
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |